Good evening and welcome to Markets Desk.
Apollo Global is moving to cap redemptions in its flagship retail private credit vehicle after withdrawal requests climbed to seventeen percent of the fund's total assets. The move revives a persistent concern in private markets — that illiquid underlying loans simply cannot be sold fast enough to meet investor exits when sentiment turns, raising broader questions about the structural fit of private credit inside retail wrappers.
Shifting to macroeconomic consequences, the Brexit vote marks its tenth anniversary today, and the scorecard is sobering. Britain has cycled through seven prime ministers, absorbed an estimated six percent structural hit to economic output, and is now navigating a demographic squeeze that compounds its trade frictions. A decade of political turbulence has left the U.K. with weaker investment flows and a productivity gap that continues to widen against European peers.
On the capital markets front, gene therapy company uniQure is launching a one hundred fifty million dollar underwritten public offering to shore up its balance sheet and fund ongoing pipeline development. Biotech equity raises of this size typically signal a company burning through cash ahead of a critical trial readout, and investors will be watching closely for what the pricing implies about near-term dilution risk.
That's the tape. Markets Desk, signing off the floor.
